Table 2.
Cardiovascular clinical presentations of hospitalized, critically ill, or fatal COVID-19 cases in identified observational studies primarily outside of China
| Study | Sample size (n) | Location | Median age, y | Hypertension, n (%) | Diabetes, n (%) | CVD, n (%) | CAD, n (%) | Atrial fibrillation, n (%) | Congestive heart failure, n (%) |
|---|---|---|---|---|---|---|---|---|---|
| Richardson et al., 202042∗ | 5700 | New York City area, USA | 63.0 | 3026 (56.6) | 1808 (33.8) | — | 595 (11.1) | — | 371 (6.9) |
| College of Health et al., 2020 (originally written (COVID-19 Surveillance Group)37† | 2848 | Italy | 81 | 1940 (68.1) | 870 (30.5) | — | 804 (28.2) | 642 (22.5) | 457 (16.0) |
| Grasselli et al., 202038 | 1591 | Lombardy region, Italy | 63 | 509 (49.0) | 180 (17.0) | 223 (21.0)‡ | — | — | — |
| Goyal et al., 202040∗ | 393 | New York City, USA | 62 | 197 (50.1) | 99 (25.2) | — | 54 (13.7) | — | 28 (7.1) |
| Myers et al., 202041∗ | 377 | Northern California, USA | 61 | 164 (43.5) | 118 (31.3) | — | — | — | 22 (5.8) |
| Onder et al., 202024† | 355 | Italy | 79§ | — | 72 (20.3) | — | 117 (30.0) | 87 (24.5) | — |
| Arentz et al., 202039† | 21 | Washington State, USA | 70§ | — | 7 (33.3) | — | — | — | 9 (42.9) |
Values are n (%), unless otherwise indicated.
CAD, coronary artery disease; COVID-19, coronavirus disease 2019; CVD, cardiovascular disease; USA, United States of America.
∗
These case series were of hospitalized COVID-19 patients.
†
These case series were of COVID-19 patients with severe or fatal disease.
‡
CVD includes cardiomyopathy and heart failure.
§
Data reported as mean.